Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-269599
Filing Date
2025-11-06
Accepted
2025-11-06 16:18:09
Documents
75
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q lctx-20250930.htm   iXBRL 10-Q 2837769
2 EX-31.1 lctx-ex31_1.htm EX-31.1 16632
3 EX-31.2 lctx-ex31_2.htm EX-31.2 14792
4 EX-32.1 lctx-ex32_1.htm EX-32.1 13941
  Complete submission text file 0001193125-25-269599.txt   11052822

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lctx-20250930.xsd EX-101.SCH 1350089
78 EXTRACTED XBRL INSTANCE DOCUMENT lctx-20250930_htm.xml XML 2101597
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12830 | Film No.: 251458563
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)